Race Oncology’s second Bisantrene patent has received “Notice of Allowance” in the US. Once ‘allowed’ in a jurisdiction, a patent can proceed to a ‘granted’ patent. The patent titled,
Race Oncology is pleased to announce the company has been invited to present at the ‘Biotech Showcase’ during the J.P. Morgan Healthcare Conference in San Francisco next week. Race Oncology Chief
Swiss biotech company TargImmune is announcing a new international research collaboration with Australia’s oldest medical research institute, the Walter and Eliza Hall Institute, to progress the
In November 2017, Race CEO Peter Molloy spoke to investors in London at the Biotech & Money conference.
What is Bisantrene and where did it come from? Click here to watch CEO Peter Molloy’s interview on Edison TV.